What changed
$NBIX — WATCHLIST 📊
Neurocrine Biosciences, Inc.
🎯 Q1 FY26 | Rev $1B | EPS $1.94 vs $1.70 🟢
💡 Consensus may have extrapolated the Q1 beat, but FY adj EPS guidance of $2.70-$2.80 implies significant earnings decline going forward due to deal costs and share dilution. The market hasn't fully priced in near-term EPS compression, creating downside risk.
📉 Reward/Risk: 2.33:1
🏢 Business Quality: 7/10 - High-quality CNS and rare-disease franchise with strong revenue growth and blockbuster Ingrezza, but acquisition adds integration and execution risk.
📊 Valuation: fair - Current EV/Sales ~5.4x on $2.75B FY revenue, P/E 57x; comparable to high-growth specialty pharma peers.
🔮 Catalyst: Soleno acquisition close and integration update; Q2 2026 earnings report
💰 Entry: $145, stop $130, target $180
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/NBIX0620